General Information of Drug (ID: DM32PJ5)

Drug Name
(S)-6-(pyrrolidin-3-ylmethoxy)-2-naphthonitrile Drug Info
Synonyms CHEMBL469551; (S)-6-(pyrrolidin-3-ylmethoxy)-2-naphthonitrile
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
44592198
TTD Drug ID
DM32PJ5

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [2]
Amitriptyline DMK7F9S Depression 6A70-6A7Z Approved [3]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [4]
Desipramine DMT2FDC Attention deficit hyperactivity disorder 6A05.Z Approved [2]
Cocaine DMSOX7I Anaesthesia 9A78.6 Approved [5]
Bupropion DM5PCS7 Depression 6A70-6A7Z Approved [6]
Tapentadol hydrochloride DMXLSH3 Acute pain MG31 Approved [7]
Venlafaxine DMR6QH0 Anxiety disorder 6B00-6B0Z Approved [6]
Trimipramine DM1SC8M Major depressive disorder 6A70.3 Approved [8]
Duloxetine DM9BI7M Depression 6A70-6A7Z Approved [9]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [2]
Amitriptyline DMK7F9S Depression 6A70-6A7Z Approved [3]
Fluoxetine DM3PD2C Bipolar depression Approved [10]
Vortioxetine DM6F1PU Major depressive disorder 6A70.3 Approved [11]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [12]
Cocaine DMSOX7I Anaesthesia 9A78.6 Approved [5]
Bupropion DM5PCS7 Depression 6A70-6A7Z Approved [6]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [10]
Nortriptyline DM4KDYJ Depression 6A70-6A7Z Approved [10]
Trazodone DMK1GBJ Depression 6A70-6A7Z Approved [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Norepinephrine transporter (NET) TTAWNKZ SC6A2_HUMAN Inhibitor [1]
Serotonin transporter (SERT) TT3ROYC SC6A4_HUMAN Inhibitor [1]

References

1 Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32.
2 Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
3 Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
4 Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8.
5 Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
6 Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
7 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
8 Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90.
9 Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
10 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
11 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
12 Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6.